AGIO News
Archived Headlines
- Agios Pharmaceuticals prices IPO at $18, above the range 07/24/13
- 12 US IPOs planned for the week of Jul 22 07/22/13
- US IPO Recap: July calendar heats up as 13 companies set terms 07/15/13
- Biotech Agios Pharmaceuticals sets terms for $75 million IPO 07/12/13
- US IPO Recap: Coty fades, Gigamon springs and 17 companies file or set terms 06/17/13
See more
Metabolic biotech Aeglea BioTherapeutics files for an $86 million IPO
Aeglea BioTherapeutics, a preclinical biotech developing enzymes for rare genetic metabolic diseases and tumors, filed on Tuesday with the SEC to raise up to $86 million in an initial public offering. Close peer Agios Pharmaceuticals (AGIO) went public in...read more
Biotech IPOs are back to normal
By almost any measure, 2013 has been a record-breaking year for biotech IPOs. The 33 biotech IPOs completed and the $2.5 billion raised are more than the totals from the previous five years combined and far exceed the levels reached at the height of the tech...read more
US IPO Recap: 11 deals price in busiest week since November 2007, eight companies set terms
US IPOs continued to make a strong showing this week, with 11 deals raising an aggregate of $1.6 billion in proceeds. It was the busiest week since the week of November 5, 2007, which saw 13 pricings. Performance was mixed, with an average total return of 7%;...read more
Agios Pharmaceuticals gains almost 74% in market debut as biotech fever continues
Agios Pharmaceuticals, a biotech developing metabolic treatments for cancer and rare genetic diseases, rose 73.8% in its market debut, making it the best biotech first-day return since Pain Therapeutics (NASDAQ: PTIE) rose 82.3% in its July 2000 debut. The...read more